DOCSLIB.ORG

TR-337: Nitrofurazone (CASRN 59-87-0) in F344/N Rats And

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
TR-337: Nitrofurazone (CASRN 59-87-0) in F344/N Rats And NATIONAL TOXICOLOGY PROGRAM Technical Report Series No. 337 TOXICOLOGY AND CARCINOGENESIS STUDIES OF NITROFURAZONE (CAS NO. 59-87-0) IN F344/N RATS AND B6C3F1 MICE (FEED STUDIES) U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health NATIONAL TOXICOLOGY PROGRAM The National Toxicology Program (NTP), established in 1978,develops and evaluates scientific information about potentially toxic and hazardous chemicals. This knowledge can be used for protecting the health of the American people and for the primary prevention of disease. By bringing to- gether the relevant programs, staff, and resources from the U.S.Public Health Service, DHHS, the National Toxicology Program has centralized and strengthened activities relating to toxicology research, testing and test developmenthalidation efforts, and the dissemination of toxicological in- formation to the public and scientific communities and to the research and regulatory agencies. The NTP is made up of four charter DHHS agencies: the National Cancer Institute (NCI), National Institutes of Health; the National Institute of En- vironmental Health Sciences (NIEHS), National Institutes of Health; the National Center for Toxicological Research (NCTR), Food and Drug Ad- ministration; and the National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control. In July 1981,the Carcino- genesis Bioassay Testing Program, NCI, was transferred to the NIEHS. Nitrofurazone, NTP TR 337 NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF NITROFURAZONE (CAS NO. 59-87-0) IN F344/N RATS AND B6C3F1 MICE (FEED STUDIES) Frank Kari, Ph.D., Chemical Manager NATIONAL TOXICOLOGY PROGRAM P.O. Box 12233 Research Triangle Park, NC 27709 June 1988 NTP TR 337 NIH Publication No. 88-2593 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health NOTETOTHEREADER This study was performed under the direction of the National Institute of Environmental Health Sci- ences as a function of the National Toxicology Program. The studies described in this Technical Re- port have been conducted in compliance with NTP chemical health and safety requirements and must meet or exceed all applicable Federal, state, and local health and safety regulations. Animal care and use were in accordance with the U.S.Public Health Service Policy on Humane Care and Use of Ani- mals. All NTP toxicology and carcinogenesis studies are subjected to a data audit before being pre- sented for public peer review. Although every effort is made to prepare the Technical Reports as accurately as possible, mistakes may occur. Readers are requested to identify any mistakes so that corrective action may be taken. Further, anyone who is aware of related ongoing or published studies not mentioned in this report is encouraged to make this information known to the NTP. Comments and questions about the National Toxicology Program Technical Reports on Toxicology and Carcinogenesis Studies should be directed to Dr. J.E. Huff,National Toxicology Program, P.O.Box 12233, Research Triangle Park, NC 27709 (919-541-3780). These NTP Technical Reports are available for sale from the National Technical Information Service, U.S.Department of Commerce, 5285 Port Royal Road, Springfield, VA 22161 (703-487-4650). Single copies of this Technical Report are available without charge (and while supplies last) from the NTP Public Information Office, National Toxicology Program, P.O. Box 12233, Research Triangle Park, NC 27709. Nitrofurazone, NTP TR 337 2 THIRTEEN-WEEK STUDIES .. ... .... .. ... .. .. ..46 TWO-YEAR STUDIES , .. .. .e.* .. s. s 8 . 41 BODY WEIQHTS, FEED CONSUMPTION, AND CLINICAL SIGNS ,,...... , , , , ....,.,41 SURVIVAL s s e s e e e e e s s s s s e s 8 8 e 9 s s e s s e 8 s 0 8 s e s e M) PATHOLOQY AND STATISTICAL ANALYSES OF RESULTS ,.,,.. ...... .. .. sa 3 Nitrofurazone, NTP TR 337 CONTENTS (Continued) PAGE IV. DISCUSSION AND CONCLUSIONS .................................................... 57 V. REFERENCES ..................................................................... 6s APPENDIXES APPENDIX A SUMMARY OF LESIONS IN MALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE .............................................. 69 APPENDIX B SUMMARY OF LESIONS IN FEMALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE .............................................. 91 APPENDIX C SUMMARY OF LESIONS IN MALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE ............................................. 111 APPENDIX D SUMMARY OF LESIONS IN FEMALE MICE IN THE TWO-YEAR FEED STUDY OF FWI"'I'OFURAZONE ............................................. 135 APPENDIX E GENETIC TOXICOLOGY OF NITROFURAZONE .............................. 159 APPENDIX F SENTINEL ANIMAL PROGRAM ............................................ 165 APPENDIX G FEED AND COMPOUND CONSUMPTION BY RATS AND MICE IN THE TWO-YEAR FEED STUDIES OF NITROFURAZONE ........................... 169 APPENDIX H INGREDIENTS. NUTRIENT COMPOSITION. AND CONTAMINANT LEVELS IN NIH 07 RAT AND MOUSE RATION ......................................... 175 APPENDIX I AUDIT SUMMARY ....................................................... 181 Nitrofurazone.NTP TR 337 4 NITROFURAZONE CAS NO. 59-87-0 C6H6N404 Molecular weight 198.1 Synonymsor Trade Names: 5-Nitro-2-furaldehyde semicarbazone; 2-[(5-Nitro-2-furanyl)methylenelhydrazinecarboxamide; Aldomycin; Amifur; Chemfuran; Coxistat; Furacin; Furacinetten; Furaplast; Furazol W; Furesol; Furracoccid; Mammex; Nefco; Nifuzon; Nitrofural; Vabrocid ABSTRACT Nitrofurazone is a synthetic furan derivative, active against a broad spectrum of bacteria, which has been widely used in veterinary and human medicine. Toxicology and carcinogenesis studies were conducted by feeding diets containing nitrofurazone (99% pure) to groups of F344/N rats and B6C3F1 mice of each sex for 14 days, 13weeks, or 2 years. Fourteen-Day and Thirteen-Week Studies: Groups of five males and five females of each species were fed diets containing 0, 630, 1,250, 2,500, 5,000, or 10,000 ppm for 14 consecutive days. Early deaths occurred in all groups of rats receiving 5,000 or 10,000ppm nitrofurazone. The surviving rats in the lower two dose groups gained weight, but weight gain was decreased as the dose of nitrofurazone was increased. Feed consumption by rats of each sex was decreased at all doses above 630 ppm. In all dosed groups, clinical signs of toxicity included rough hair coats and lethargy. At doses of 2,500 ppm and above, rats of each sex exhibited intermittent episodes of seizures and lethargy. All mice that received 2,500, 5,000, or 10,000 ppm nitrofurazone and 315 males that received 1,250 ppm died before the end of the 1Cday studies; the surviving dosed mice (except females at 630 ppm) lost weight. A dose-related decrease in feed consumption was observed at all doses above 630 ppm. Clinical signs included rough hair coats and convulsive seizures. In the 13-week studies, groups of 10 rats of each sex were given diets containing 0, 150, 310, 620, 1,250,or 2,500 ppm nitrofurazone, No deaths were observed and all animals gained weight, but the magnitude of weight gain was dose dependent with decrements in final mean body weight for the highest dose group reaching 55% in males and 36% in females. Other evidence of chemically related toxicity included convulsive seizures, osteoporosis, degenerative arthropathy, and gonadal hypo- plasia in both sexes at the two highest doses. Groups of 10mice of each sex were given diets containing 0,70, 150,310,620, or 1,250 ppm nitrofura- zone for 13weeks. Early deaths were observed in the two highest dose groups of each sex. The final mean body weights of male and female mice in the 1,250-ppm groups were about 20% lower than those of the controls; weight gains of the other dosed mice were comparable to those of the controls. Stimulus-induced convulsive seizures were observed for all mice in the two highest dose groups. Tes- ticular hypoplasia was observed in the two highest dose groups of male mice. Body Weight and Survival in the Two-year Studies: Dietary concentrations for the 2-year studies were 0,310, or 620 ppm for rats and 0,150, or 310 ppm for mice (60 animals per dose group). Mean 5 Nitrofurazone, NTP TR 337 body weights of high dose male rats were lower than those of the controls after week 39; mean body weights of low dose male rats and of the controls were comparable throughout the study. Final mean body weights of low and high dose female rats were 9% and 21% lower than those of the controls. Dosed rats consumed less feed than did the controls. The average amount of nitrofurazone consumed per day was approximately 11-12 or 24-26 mg/kg by low or high dose male and female rats. The sur- vival of the high dose group of male rats was lower than that of the controls after week 92 (final sur- vival--male: control, 33/50; low dose, 30/50; high dose, 20150; female: 28/50; 37/50; 31/50). Mean body weights of dosed mice were similar to or somewhat greater than those of the controls throughout most of the studies. The average daily feed consumption by dosed mice was similar to that of controls. The average amount of nitrofurazone consumed per day was approximately 14-16 or 29-33 mg/kg for low or high dose male and female mice. The survival of the high dose group of male mice was lower than that of the controls after week 88 (final survival--male: 39/50; 31/50; 27/50; fe- male: 39/50; 40/50; 35/50). In mice of each sex, nitrofurazone administration induced stimulus-sensitive convulsive seizures be- ginning at week 4 or 5 for high dose mice and week 24 for low dose female mice. These seizures were observed primarily in the first year of the study. Nonneoplastic and Neoplastic Effects in the Two-year Studies: Degenerative changes involving the vertebral and femoro-tibial (knee) joints were observed at increased incidences in dosed rats. The de- generative changes primarily affected the articular cartilage and were similar to those seen in the 13- week studies. Degeneration of the sternal synchondroses was increased in high dose female rats.
Load more

Recommended publications
  • The Role of Nanobiosensors in Therapeutic Drug Monitoring
    Journal of Personalized Medicine Review Personalized Medicine for Antibiotics: The Role of Nanobiosensors in Therapeutic Drug Monitoring Vivian Garzón 1, Rosa-Helena Bustos 2 and Daniel G. Pinacho 2,* 1 PhD Biosciences Program, Universidad de La Sabana, Chía 140013, Colombia; [email protected] 2 Therapeutical Evidence Group, Clinical Pharmacology, Universidad de La Sabana, Chía 140013, Colombia; [email protected] * Correspondence: [email protected]; Tel.: +57-1-8615555 (ext. 23309) Received: 21 August 2020; Accepted: 7 September 2020; Published: 25 September 2020 Abstract: Due to the high bacterial resistance to antibiotics (AB), it has become necessary to adjust the dose aimed at personalized medicine by means of therapeutic drug monitoring (TDM). TDM is a fundamental tool for measuring the concentration of drugs that have a limited or highly toxic dose in different body fluids, such as blood, plasma, serum, and urine, among others. Using different techniques that allow for the pharmacokinetic (PK) and pharmacodynamic (PD) analysis of the drug, TDM can reduce the risks inherent in treatment. Among these techniques, nanotechnology focused on biosensors, which are relevant due to their versatility, sensitivity, specificity, and low cost. They provide results in real time, using an element for biological recognition coupled to a signal transducer. This review describes recent advances in the quantification of AB using biosensors with a focus on TDM as a fundamental aspect of personalized medicine. Keywords: biosensors; therapeutic drug monitoring (TDM), antibiotic; personalized medicine 1. Introduction The discovery of antibiotics (AB) ushered in a new era of progress in controlling bacterial infections in human health, agriculture, and livestock [1] However, the use of AB has been challenged due to the appearance of multi-resistant bacteria (MDR), which have increased significantly in recent years due to AB mismanagement and have become a global public health problem [2].
    [Show full text]
  • Nitrofurazone
    PATIENT INFORMATION SHEET Nitrofurazone (N-005) Your patch testing results indicate that you have a contact allergy to Nitrofurazone . It is important that you familiarize yourself with this chemical and take steps to avoid coming in contact with it. i What is Nitrofurazone and where is it found? This chemical is used as a topical bactericide for surface infections. If is also used in anti ‐infective therapy for second and third degree burns and in skin grafting. It is also an antibacterial agent for the treatment or prevention of infections in a variety of conditions involving skin, eyes, ears, nose and genitourinary tract. It is used on pyodermas, ulcers and wounds. Further research may identify additional product or industrial usages of this chemical. i What else is Nitrofurazone called? This chemical can be identified by different names, including: 2‐[(5 ‐Nitro ‐2‐furanyl)methylene]‐hydrazinecarboxamide 5‐nitro ‐2‐furfuraldehyde semicarbazone (5 ‐nitro ‐2‐furfurylideneamino)urea 5‐nitrofurfural semicarbazone 5‐Nitro ‐2‐furaldehyde Semicarbazone 6‐nitrofuraldehyde semicarbazide 5‐nitrofuraldehyde semicarbazide NF 5‐nitrofuran ‐2‐aldehyde semicarbazone NF ‐7 5‐nitro ‐2‐furancarboxaldehyde semicarbazone NFS This may not be a complete list as manufacturers introduce and delete chemicals from their product lines. THINGS YOU CAN DO TO HELP MANAGE YOUR CONTACT ALLERGY Be vigilant read the product label. Always take the time to read the ingredient listing on product packages. This should be your first step each time you purchase a product as manufacturers sometimes change product ingredients. If you have any concerns ask your pharmacist or your doctor. Test the product first.
    [Show full text]
  • Against the Plasmodium Falciparum Apicoplast
    A Systematic In Silico Search for Target Similarity Identifies Several Approved Drugs with Potential Activity against the Plasmodium falciparum Apicoplast Nadlla Alves Bispo1, Richard Culleton2, Lourival Almeida Silva1, Pedro Cravo1,3* 1 Instituto de Patologia Tropical e Sau´de Pu´blica/Universidade Federal de Goia´s/Goiaˆnia, Brazil, 2 Malaria Unit/Institute of Tropical Medicine (NEKKEN)/Nagasaki University/ Nagasaki, Japan, 3 Centro de Mala´ria e Doenc¸as Tropicais.LA/IHMT/Universidade Nova de Lisboa/Lisboa, Portugal Abstract Most of the drugs in use against Plasmodium falciparum share similar modes of action and, consequently, there is a need to identify alternative potential drug targets. Here, we focus on the apicoplast, a malarial plastid-like organelle of algal source which evolved through secondary endosymbiosis. We undertake a systematic in silico target-based identification approach for detecting drugs already approved for clinical use in humans that may be able to interfere with the P. falciparum apicoplast. The P. falciparum genome database GeneDB was used to compile a list of <600 proteins containing apicoplast signal peptides. Each of these proteins was treated as a potential drug target and its predicted sequence was used to interrogate three different freely available databases (Therapeutic Target Database, DrugBank and STITCH3.1) that provide synoptic data on drugs and their primary or putative drug targets. We were able to identify several drugs that are expected to interact with forty-seven (47) peptides predicted to be involved in the biology of the P. falciparum apicoplast. Fifteen (15) of these putative targets are predicted to have affinity to drugs that are already approved for clinical use but have never been evaluated against malaria parasites.
    [Show full text]
  • Use of Polyphenolic Compounds in Dermatologic Oncology Adilson Costa, Emory University Michael Yi Bonner, Emory University Jack Arbiser, Emory University
    Use of Polyphenolic Compounds in Dermatologic Oncology Adilson Costa, Emory University Michael Yi Bonner, Emory University Jack Arbiser, Emory University Journal Title: American Journal of Clinical Dermatology Volume: Volume 17, Number 4 Publisher: Adis | 2016-08-01, Pages 369-385 Type of Work: Article | Post-print: After Peer Review Publisher DOI: 10.1007/s40257-016-0193-5 Permanent URL: https://pid.emory.edu/ark:/25593/s99z6 Final published version: http://dx.doi.org/10.1007/s40257-016-0193-5 Copyright information: © 2016, Springer International Publishing Switzerland (outside the USA). Accessed September 26, 2021 2:39 AM EDT HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Am J Clin Manuscript Author Dermatol. Author Manuscript Author manuscript; available in PMC 2018 April 16. Published in final edited form as: Am J Clin Dermatol. 2016 August ; 17(4): 369–385. doi:10.1007/s40257-016-0193-5. Use of Polyphenolic Compounds in Dermatologic Oncology Adilson Costa1, Michael Yi Bonner1, and Jack L. Arbiser1 1Department of Dermatology, Emory University School of Medicine, Atlanta Veterans Administration Medical Center, Winship Cancer Institute, 101 Woodruff Circle, Atlanta, GA 30322, USA Abstract Polyphenols are a widely used class of compounds in dermatology. While phenol itself, the most basic member of the phenol family, is chemically synthesized, most polyphenolic compounds are found in plants and form part of their defense mechanism against decomposition. Polyphenolic compounds, which include phenolic acids, flavonoids, stilbenes, and lignans, play an integral role in preventing the attack on plants by bacteria and fungi, as well as serving as cross-links in plant polymers. There is also mounting evidence that polyphenolic compounds play an important role in human health as well.
    [Show full text]
  • Gene-Drug Interactions and the Evolution of Antibiotic Resistance
    Gene-Drug Interactions and the Evolution of Antibiotic Resistance The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Palmer, Adam Christopher. 2012. Gene-Drug Interactions and the Evolution of Antibiotic Resistance. Doctoral dissertation, Harvard University. Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10436292 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA © - Adam Christopher Palmer All rights reserved. Professor Roy Kishony Adam Christopher Palmer Gene-drug interactions and the evolution of antibiotic resistance Abstract The evolution of antibiotic resistance is shaped by interactions between genes, the chemical environment, and an antibiotic's mechanism of action. This thesis explores these interactions with experiments, theory, and analysis, seeking a mechanistic understanding of how different interactions between genes and drugs can enhance or constrain the evolution of antibiotic resistance. Chapter 1 investigates the effects of the chemical decay of an antibiotic. Tetracycline resistant and sensitive bacteria were grown competitively in the presence of tetracycline and its decay products. Antibiotic decay did not only remove selection for resistance, but long- lived decay products favored tetracycline sensitivity by inducing costly drug efflux pumps in the resistant strain. Selection against resistance by antibiotic-related compounds may contribute to the coexistence of drug-sensitive and resistant bacteria in nature. Chapter 2 investigates how genetic interactions can favor particular combinations of resistance-conferring mutations.
    [Show full text]
  • G6PD Deficiency Reference Guide
    Medications to Avoid Safe to take But only in normal therapeutic doses [!!!] G6PD Deficiency Reference Guide Analgesics / Antipyretics acetanilid, acetophenetidin (phenacetin), (Quoted from Ernest Beutler, M.D., “Glucose-6- amidopyrine (aminopyrine) *, Phosphate Dehydrogenase Deficiency,” in Eryth- What is G6PD Deficiency? antipyrine *, aspirin *, phenacetin, rocyte disorders: Anemias due to increased destruc- probenicid, pyramidone tion of erythrocytes with enzyme deficiencies, p. 598.) Glucose-6-phosphate dehydrogenase likely to be affected by this condition than (G6PD) deficiency is the most common are females. Genetic testing is available to Miscellaneous Acetaminophen (paracetamol, Tylenol, human enzyme deficiency; it affects an identify a deficiency in G6PD in both alpha-methyldopa, ascorbic acid *, Tralgon, hydroxyacetanilide), estimated 400 million people worldwide. males and females. dimercaprol (BAL), hydralazine, Acetophenetidin (phenacetin), G6PD deficiency is also known as It is very important to tell any doctor or mestranol, methylene blue, nalidixic acid, Acetylsalicylic acid (aspirin) *, “favism,” since G6PD deficient individu- other health professional (such as nurse or naphthalene, niridazole, Aminopyrine (Pyramidon, amidopyrine) *, als are also allergic to fava beans. pharmacist) that you have G6PD Defi- phenylhydrazine, toluidine blue, Antazoline (Antistine), G6PD deficiency is a genetic condition ciency to avoid a possible harmful reaction trinitrotoluene, urate oxidase, vitamin Antipyrine *, that is inherited in an
    [Show full text]
  • Detection of Carcinogens As Mutagens in the Salmonella/Microsome Test
    Proc. Nat. Acad. Sci. USA Vol. 73, No. 3, pp. 950-954, March 1976 Medical Sciences Detection of carcinogens as mutagens in the Salmonella/microsome test: Assay of 300 chemicals: Discussion* (prevention of cancer and genetic defects/somatic mutation/environmental insult to DNA) JOYCE MCCANN AND BRUCE N. AMES Department of Biochemistry, University of California, Berkeley, Calif. 94720 Contributed by Bruce N. Ames, January 7, 1976 ABSTRACT About 300 carcinogens and non-carcinogens Non-Carcinogens. Classification as to non-carcinogenicity of a wide variety of chemical types have been tested for mu- is usually difficult because of the varying completeness and tagenicity in the simple Salmonella/microsome test. The test uses bacteria as sensitive indicators of DNA damage, and modes of treatment in many studies and the statistical limi- mammalian liver extracts for metabolic conversion of carcin- tations inherent in animal tests (4, 8-10). Recent criteria for ogens to their active mutagenic forms. There is a high corre- adequate carcinogenicity tests are much more stringent (4, lation between carcinogenicity and mutagenicity: 90% 8-10). The test should be of adequate duration (lifetime pre- (157/175) of the carcinogens were mutagenic in the test, in- ferred in rodents) in at least two animal species, at several cluding almost all of the known human carcinogens that dose levels, and positive controls should be of the same gen- were tested. Despite the severe limitations inherent in defin- ing non-carcinogenicity, few "non-carcinogens" showed any eral chemical type as the chemical under test. The applica- degree of mutagenicity [McCann et a]. (1975) Proc.
    [Show full text]
  • Use of Antibiotics in Ornamental Fish Aquaculture1 Roy P
    Cir 84 Use of Antibiotics in Ornamental Fish Aquaculture1 Roy P. E. Yanong2 Introduction based on their response to a protocol called gram staining. Gram-positive bacteria stain blue, and gram-negative Antibiotics are very useful additions to any fish-health bacteria stain pink. They stain differently because each manager’s toolbox, but they are only tools and not ‘magic group has a different type of outer structure known as the bullets.’ The ability of antibiotics to help eliminate a fish cell wall. This difference is important for the producer disease depends on a number of factors: 1) Does the and aquaculturist because some antibiotics work better problem actually have a bacterial component? 2) Are the against gram-positive bacteria and others work better bacteria involved sensitive to the antibiotic chosen? 3) Are against gram-negative bacteria. Most bacteria that infect the proper dosage and treatment intervals being used? 4) fish are gram-negative, including Aeromonas hydrophila, Have other contributing stresses been removed or reduced? Aeromonas salmonicida, Flavobacterium columnare (which causes columnaris), Vibrio, and Pseudomonas species. (See Antibiotics, in and of themselves, do not cure a fish. Antibi- UF/IFAS Fact Sheets FA-14 Aeromonas Infections, FA-31 otics merely control the population growth of bacteria in a Vibrio Infections of Fish and FA-11 Columnaris disease). fish long enough for its immune system to eliminate them. The major group of gram-positive bacteria that cause Before antibiotics are even considered, sources of stress disease in fish are Streptococcus. (See UF/IFAS Circular 57 such as poor water quality (including drastic temperature Streptococcal Infections in Fish.) change), nutrition, genetics, and handling or transport must A third group, the acid-fast bacteria, which includes be removed or reduced.
    [Show full text]
  • Downloads/Drugs/Guidancecomplianceregulatoryinformation/Guidances/UCM347725.Pdf
    Safety Assessment of Hydrogen Peroxide as Used in Cosmetics Status: Tentative Report for Public Comment Release Date: June 28, 2018 Panel Meeting Date: September 24-25, 2018 All interested persons are provided 60 days from the above date to comment on this safety assessment and to identify additional published data that should be included or provide unpublished data which can be made public and included. Information may be submitted without identifying the source or the trade name of the cosmetic product containing the ingredient. All unpublished data submitted to CIR will be discussed in open meetings, will be available at the CIR office for review by any interested party and may be cited in a peer-reviewed scientific journal. Please submit data, comments, or requests to the CIR Executive Director, Dr. Bart Heldreth. The 2018 Cosmetic Ingredient Review Expert Panel members are: Chair, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Ronald A. Hill, Ph.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; James G. Marks, Jr., M.D.; Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The CIR Executive Director is Bart Heldreth Ph.D. This report was prepared by Lillian C. Becker, former Scientific Analyst/Writer, and Priya A. Cherian, Scientific Analyst/Writer. © Cosmetic Ingredient Review 1620 L Street, NW, Suite 1200 ♢ Washington, DC 20036-4702 ♢ ph 202.331.0651 ♢ fax 202.331.0088 [email protected] ABSTRACT: The Cosmetic Ingredient Review (CIR) Expert Panel (Panel) reviewed the safety of Hydrogen Peroxide, which is reported to function in cosmetics as an antimicrobial agent, cosmetic biocide, oral health care agent, and oxidizing agent.
    [Show full text]
  • Federal Register / Vol. 62, No. 158 / Friday, August 15, 1997 / Rules and Regulations
    43820 Federal Register / Vol. 62, No. 158 / Friday, August 15, 1997 / Rules and Regulations ENVIRONMENTAL PROTECTION standard can modify these guidelines as Agency experts and, in some instances, AGENCY needed for an individual test substance. presented at domestic and international The Agency uses a system where colloquia to solicit the views of 40 CFR Part 799 standardized guidelines are organized recognized experts and the regulated by testing endpoint and codified in a community. The draft harmonized [OPPTS±42193; FRL±5719±5] subpart of this part. When a test rule is guidelines are made available as public RIN 2070±AB76 promulgated, the test standard specified drafts. A notice is published in the in the test rule cross-references the Federal Register announcing their Toxic Substances Control Act Test guideline for the bulk of the testing availability and soliciting public Guidelines requirements. In this context, the public comment. is given notice of, and an opportunity to Seven of the 11 health effects test AGENCY: Environmental Protection comment on, the guidelines as they are guidelines that are being codified in Agency (EPA). applied in chemical-specific test rules. subpart H of 40 CFR part 799 have their ACTION: Final rule. This approach eliminates the need to origin in this harmonization process. A repeat the same test specifications for notice was published in the Federal SUMMARY: This rule establishes 11 Toxic each substance-specific test rule since Register of June 20, 1996, (61 FR 31522 Substances Control Act (TSCA) health most of the specifications for testing do (FRL±5367±7)) announcing the effects test guidelines in the Code of not change across substances.
    [Show full text]
  • 345 Part 524—Ophthalmic and Top- Ical Dosage Form New Ani- Mal Drugs
    Food and Drug Administration, HHS Pt. 524 (3) Steers fed in confinement for slaugh- PART 524—OPHTHALMIC AND TOP- ter—(i) Amount. 72 mg zeranol (one im- ICAL DOSAGE FORM NEW ANI- plant consisting of 6 pellets, each pel- MAL DRUGS let containing 12 mg zeranol) per im- plant dose. Sec. (ii) Indications for use. For increased 524.86 Amitraz. rate of weight gain and improved feed 524.154 Bacitracin, neomycin, and poly- efficiency. myxin B ophthalmic ointment. (iii) Limitations. Implant 524.155 Bacitracin, neomycin, polymyxin B, subcutaneously in ear only. Safety and and hydrocortisone ophthalmic oint- effectiveness have not been established ment. 524.390 Chloramphenicol ophthalmic oint- in veal calves. A withdrawal period has ment. not been established for this product in 524.402 Chlorhexidine. preruminating calves. Do not use in 524.450 Clotrimazole. calves to be processed for veal. 524.463 Copper naphthenate. (4) Pasture cattle (slaughter, stocker, 524.575 Cyclosporine ophthalmic ointment. feeder steers, and heifers)—(i) Amount. 524.590 Diclofenac. 138 mg zeranol (one implant consisting 524.660 Dimethyl sulfoxide. 524.770 Doramectin. of 7 pellets, each of 6 pellets containing 524.775 Emodepside and praziquantel. 20 mg zeranol and a seventh pellet con- 524.802 Enrofloxacin and silver sulfadiazine taining 18 mg zeranol) per implant otic emulsion. dose. 524.814 Eprinomectin. (ii) Indications for use. For increased 524.900 Famphur. rate of weight gain. 524.920 Fenthion. (iii) Limitations. Implant 524.916 Fentanyl. 524.955 Florfenicol, terbinafine, and subcutaneously in ear only. Safety and betamethasone acetate otic gel. effectiveness have not been established 524.957 Florfenicol, terbinafine, and in veal calves.
    [Show full text]
  • Endocrine Disruption
    Screening for Estrogen-mimicking Chemicals: An Assessment of the E-screen and Its Implications by Edmond Toy B.A.S. Civil Engineering and Values, Technology, Science, and Society Stanford University, 1993 Submitted to the Department of Civiland Environmental Engineering in Partial Fulfillment of the Requirements for the Degrees of Master of Science in Technology and Policy and Master of Science in Civil and Environmental Engineering at the Massachusetts Institute of Technology September 1995 © 1995 Massachusetts Institute of Technology. All rights reserved. Signature of Author: Department of Civil and Enviromental Engineering August 11, 1995 r'o / I' i /E Certified by: David H. Marks, Ph.D. James Mason Crafts Professor of Civil and Environmental Engineering Director, Program in Environmental Engineering Education and Research Thesis Supervisor A/ Certified by: Richard de Neufville, Ph.D. Professor of Civil and Environmental Engineering Chairman, Technology and Policy Program Accepted by: / 1- ! J'dseph M. Sussman, Ph.D. Chairman, Departmental Committee on Graduate Studies ;;ASSACHUS'T S INSTIlU'rE OF TECHNOLOGY Barker Eng OCT 25 1995 Screening for Estrogen-mimicking Chemicals: An Assessment of the E-screen and Its Implications by Edmond Toy Submitted to the Department of Civil and Environmental Engineering on August 11, 1995 in Partial Fulfillment of the Requirements for the Degrees of Master of Science in Technology and Policy and Master of Science in Civil and Environmental Engineering There is a growing concern that chemicals in the environment may be affecting the endocrine systems of wildlife and humans. Some scientists believe that these endocrine disrupting chemicals are responsible for a wide variety of cancer and noncancer effects.
    [Show full text]